Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Cantor Fitzgerald raised their FY2021 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a research report issued on Tuesday, April 13th. Cantor Fitzgerald analyst A. Young now forecasts that the company will post earnings of ($4.41) per share for the year, up from their previous forecast of ($4.47).
Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Wednesday, February 24th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $1.40. The firm had revenue of $250.00 million for the quarter, compared to analysts’ expectations of $184.54 million.
Shares of Apellis Pharmaceuticals stock opened at $45.57 on Thursday. The firm has a market capitalization of $3.66 billion, a PE ratio of -6.14 and a beta of 1.47. Apellis Pharmaceuticals has a twelve month low of $25.49 and a twelve month high of $58.47. The firm’s 50-day moving average price is $44.57 and its 200 day moving average price is $44.70. The company has a current ratio of 9.86, a quick ratio of 9.86 and a debt-to-equity ratio of 3.34.
A number of hedge funds and other institutional investors have recently bought and sold shares of APLS. Norges Bank acquired a new position in Apellis Pharmaceuticals in the fourth quarter valued at $37,906,000. Ghost Tree Capital LLC purchased a new position in Apellis Pharmaceuticals during the fourth quarter worth about $18,590,000. Renaissance Technologies LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at about $12,373,000. FIL Ltd boosted its holdings in Apellis Pharmaceuticals by 146.8% in the 4th quarter. FIL Ltd now owns 319,154 shares of the company’s stock valued at $18,256,000 after purchasing an additional 189,835 shares in the last quarter. Finally, Avidity Partners Management LP increased its position in Apellis Pharmaceuticals by 24.2% during the 4th quarter. Avidity Partners Management LP now owns 774,000 shares of the company’s stock worth $44,273,000 after purchasing an additional 150,700 shares during the period. Institutional investors own 81.20% of the company’s stock.
In other Apellis Pharmaceuticals news, VP Nicole D. Perry sold 2,000 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, February 9th. The shares were sold at an average price of $50.00, for a total value of $100,000.00. Following the transaction, the vice president now directly owns 4,500 shares in the company, valued at $225,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alec Machiels sold 2,500 shares of Apellis Pharmaceuticals stock in a transaction on Monday, March 15th. The shares were sold at an average price of $46.77, for a total transaction of $116,925.00. Following the completion of the transaction, the director now owns 672,044 shares in the company, valued at $31,431,497.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,350 shares of company stock valued at $847,991. 9.50% of the stock is owned by corporate insiders.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.